Atlas Trials

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

Clinical trial NCT04474197 · COMPLETED

Trial details

NCT number
NCT04474197
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Alpha1-Antitrypsin Deficiency
Start date
2020-07-24
Primary completion
2021-05-04
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.